ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation

January 6, 2022 GMT

NEW YORK--(BUSINESS WIRE)--Jan 6, 2022--

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT). Investors who purchased Applied Therapeutics shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/aplt.

The investigation concerns whether Applied Therapeutics and certain of its officers and/or directors have violated federal securities laws.

On January 3, 2022, Applied Therapeutics issued a press release “provid[ing] a regulatory update on the AT-007 Galactosemia program.” In the press release, Applied Therapeutics announced that “[f]ollowing discussions with the FDA at the end of the year, the Company has decided to hold on submitting an NDA for AT-007 for treatment of Galactosemia pending additional discussions with the agency. Although the Galactosemia program had previously been discussed in the context of an NDA for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval.” On this news, Applied Therapeutics’ stock price fell $1.77 per share, or 28.46%, over the following two trading sessions, closing at $4.45 per share on January 5, 2022.

ADVERTISEMENT

If you are aware of any facts relating to this investigation or purchased Applied Therapeutics shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/aplt. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20220106005695/en/

CONTACT: Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 |info@bgandg.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Copyright Business Wire 2022.

PUB: 01/06/2022 11:45 AM/DISC: 01/06/2022 11:47 AM

http://www.businesswire.com/news/home/20220106005695/en